AC Immune (NASDAQ:ACIU) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

AC Immune (NASDAQ:ACIU) posted its earnings results on Wednesday. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13, FiscalAI reports. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The company had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $10.92 million.

AC Immune Price Performance

Shares of ACIU opened at $2.29 on Thursday. The company has a market capitalization of $233.05 million, a P/E ratio of -2.79 and a beta of 1.59. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average of $2.38 and a 200 day moving average of $2.78. AC Immune has a twelve month low of $2.03 and a twelve month high of $4.00.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ACIU. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research report on Wednesday. Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Finally, HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.50.

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the transaction, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently added to or reduced their stakes in the stock. EFG International AG bought a new position in shares of AC Immune during the 4th quarter valued at $41,000. Private Advisor Group LLC purchased a new position in shares of AC Immune in the 3rd quarter worth $48,000. Sei Investments Co. bought a new stake in shares of AC Immune in the second quarter worth $51,000. Goldman Sachs Group Inc. grew its holdings in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after acquiring an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP bought a new stake in shares of AC Immune in the third quarter worth $63,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.